SCHEMBL3673146

SCHEMBL3673146

CCCC[Sn](CCCC)(CCCC)c1nnn(CC2CCOCC2)c1-c1ccccc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.49
TLR7 Q9NYK1 4/20 0.36
PIK3CD O00329 1/20 0.33
PIK3R2 O00459 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
PIK3R5 Q8WYR1 1/20 0.33
PIK3R3 Q92569 1/20 0.33
BRD4 O60885 1/20 0.32
BAZ2A Q9UIF9 1/20 0.32
RIPK2 O43353 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CNR2 P34972 3/20 0.32
TDO2 P48775 2/20 0.32
PDE8B O95263 1/20 0.31
SIGMAR1 Q99720 2/20 0.31
GRM2 Q14416 1/20 0.31
TLR8 Q9NR97 1/20 0.31
AGTR1 P30556 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295575 0.80 CDC7 (0.49) CDC7TLR7
SCHEMBL4292554 0.77 CDC7 (0.44) CDC7TDO2GRM2
SCHEMBL4291525 0.76 PDE8B (0.40) TLR7CNR2PDE8B
SCHEMBL3671620 0.70 CDC7 (0.39) CDC7TDO2GRM2
SCHEMBL4291348 0.67 CDC7 (0.61) CDC7BRD4BAZ2ATDO2SIGMAR1
SCHEMBL4291305 0.66 CDC7 (1.00) CDC7
SCHEMBL3669940 0.63 CYP19A1 (0.48) CDC7TDO2GRM2
SCHEMBL3667322 0.62 ROCK2 (0.43) CDC7CNR2GRM2
SCHEMBL1500684 0.62 ALDH1A1 (0.39)
SCHEMBL4292592 0.62 GRM2 (0.41) CDC7NPSR1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885TLR7 4479/4885PIK3CD 152/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885TLR7 4479/4885PIK3CD 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.